<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35419092</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1844-3117</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of medicine and life</Title><ISOAbbreviation>J Med Life</ISOAbbreviation></Journal><ArticleTitle>Diet, fibers, and probiotics for irritable bowel syndrome.</ArticleTitle><Pagination><StartPage>174</StartPage><EndPage>179</EndPage><MedlinePgn>174-179</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.25122/jml-2022-0028</ELocationID><Abstract><AbstractText>Many aspects make irritable bowel syndrome (IBS) challenging for both patients and physicians. The unclear pathogenesis with many pathways to be explored, bothering symptoms that affect the quality of life, and many subtypes of the condition are only a few reasons that make IBS difficult to control and obtain satisfactory results. Treatment options start with general advice for lifestyle, continue with non-pharmaceutical treatments, and finally touch classic treatments. In this review, pharmaceutical treatment options are not accounted for. Consensus groups and meta-analyses have concluded guidelines that overall are the same, with variations in the strength of recommendations and some cultural and geographical particularities. Dietary interventions, probiotics, and fibers can be seen as non-pharmaceutical treatments that coexist in various protocols because of the relevant evidence regarding their efficacy in treating IBS symptoms.</AbstractText><CopyrightInformation>&#xa9;2022 JOURNAL of MEDICINE and LIFE.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Galica</LastName><ForeName>Adelina Nicoleta</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>2 Department of Internal Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nursing, Faculty of Natural and Human Sciences, Fan S. Noli University, Kor&#xe7;e, Albania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galica</LastName><ForeName>Reitano</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Regional Hospital Kor&#xe7;e, Kor&#xe7;e, Albania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dumitra&#x219;cu</LastName><ForeName>Dan Lucian</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>2 Department of Internal Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Romania</Country><MedlineTA>J Med Life</MedlineTA><NlmUniqueID>101477617</NlmUniqueID><ISSNLinking>1844-122X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004187">Disaccharides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009005">Monosaccharides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D004032" MajorTopicYN="N">Diet</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004187" MajorTopicYN="N">Disaccharides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005285" MajorTopicYN="N">Fermentation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009005" MajorTopicYN="N">Monosaccharides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FGID &#x2013; functional gastrointestinal disorders</Keyword><Keyword MajorTopicYN="N">FODMAP</Keyword><Keyword MajorTopicYN="N">FODMAP &#x2013; fermentable oligosaccharides, disaccharides, monosaccharides, and polyols</Keyword><Keyword MajorTopicYN="N">IBS &#x2013; C irritable bowel syndrome subtype with constipation</Keyword><Keyword MajorTopicYN="N">IBS &#x2013; D irritable bowel syndrome subtype with diarrhea</Keyword><Keyword MajorTopicYN="N">IBS &#x2013; irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">LFD &#x2013; low FODMAP diet</Keyword><Keyword MajorTopicYN="N">NICE/mNICE &#x2013; National Institute for Health and Care Excellence/modified diet</Keyword><Keyword MajorTopicYN="N">gut microbiota</Keyword><Keyword MajorTopicYN="N">irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">non-pharmacological therapy</Keyword><Keyword MajorTopicYN="N">probiotics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>14</Day><Hour>5</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35419092</ArticleId><ArticleId IdType="pmc">PMC8999090</ArticleId><ArticleId IdType="doi">10.25122/jml-2022-0028</ArticleId><ArticleId IdType="pii">JMedLife-15-174</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Drossman DA. Functional gastrointestinal disorder and the Rome IV process. Functional gastrointestinal disorders. In: Drossman DA, Chang L, Chey WD, et al., editors. Disorders of brain-gut interaction. 4th. Vol. 1. Raleigh, NC: Rome Foundation; 2016. pp. 1&#x2013;32.</Citation></Reference><Reference><Citation>Enck P, Aziz Q, Barbara G, Farmer AD, et al. Irritable bowel syndrome. Nat Rev Dis Primers 2016;2:16014. doi: 10.1038/nrdp.2016.14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2016.14</ArticleId><ArticleId IdType="pmc">PMC5001845</ArticleId><ArticleId IdType="pubmed">27159638</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperber AD, Dumitrascu DL, Fukudo S, Gerson C, et al. The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: A Rome Foundation working team literature review. Gut. 2017;66(6):1075&#x2013;1082. doi: 10.1136/gutjnl-2015-311240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2015-311240</ArticleId><ArticleId IdType="pubmed">26818616</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712&#x2013;721.e4. doi: 10.1016/j.cgh.2012.02.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2012.02.029</ArticleId><ArticleId IdType="pubmed">22426087</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2021;160(1):99&#x2013;114.e3. doi: 10.1053/j.gastro.2020.04.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.04.014</ArticleId><ArticleId IdType="pubmed">32294476</ArticleId></ArticleIdList></Reference><Reference><Citation>Palsson OS, Whitehead W, T&#xf6;rnblom H, Sperber AD, Simren M. Prevalence of Rome IV Functional Bowel Disorders Among Adults in the United States, Canada, and the United Kingdom. Gastroenterology. 2020;158(5):1262&#x2013;1273.e3. doi: 10.1053/j.gastro.2019.12.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2019.12.021</ArticleId><ArticleId IdType="pubmed">31917991</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh P, Staller K, Barshop K, Dai E, et al. Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation. World J Gastroenterol. 2015;21(26):8103&#x2013;8109. doi: 10.3748/wjg.v21.i26.8103.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v21.i26.8103</ArticleId><ArticleId IdType="pmc">PMC4499353</ArticleId><ArticleId IdType="pubmed">26185382</ArticleId></ArticleIdList></Reference><Reference><Citation>Drossman DA, Chang L, Schneck S, Blackman C, et al. A focus group assessment of patient perspectives on irritable bowel syndrome and illness severity. Dig Dis Sci. 2009;54(7):1532&#x2013;1541. doi: 10.1007/s10620-009-0792-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-009-0792-6</ArticleId><ArticleId IdType="pubmed">19337833</ArticleId></ArticleIdList></Reference><Reference><Citation>Black CJ, Ford AC. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol. 2020;17(8):473&#x2013;486. doi: 10.1038/s41575-020-0286-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-020-0286-8</ArticleId><ArticleId IdType="pubmed">32296140</ArticleId></ArticleIdList></Reference><Reference><Citation>Surdea-Blaga T, Cozma-Petrut A, Dumitra&#x15f;cu DL. Dietary interventions and irritable bowel syndrome &#x2013; what really works?. Curr Opin Gastroenterol. 2021;37(2):152&#x2013;157. doi: 10.1097/MOG.0000000000000706.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MOG.0000000000000706</ArticleId><ArticleId IdType="pubmed">33332914</ArticleId></ArticleIdList></Reference><Reference><Citation>Cozma-Petru&#x163; A, Loghin F, Miere D, Dumitra&#x15f;cu DL. Diet in irritable bowel syndrome: What to recommend, not what to forbid to patients!. World J Gastroenterol. 2017;23(21):3771&#x2013;3783. doi: 10.3748/wjg.v23.i21.3771.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v23.i21.3771</ArticleId><ArticleId IdType="pmc">PMC5467063</ArticleId><ArticleId IdType="pubmed">28638217</ArticleId></ArticleIdList></Reference><Reference><Citation>Johannesson E, Jakobsson Ung E, Sadik R, Ringstr&#xf6;m G. Experiences of the effects of physical activity in persons with irritable bowel syndrome (IBS): a qualitative content analysis. Scand J Gastroenterol. 2018 Oct-Nov;53(10-11):1194&#x2013;1200. doi: 10.1080/00365521.2018.1519596.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00365521.2018.1519596</ArticleId><ArticleId IdType="pubmed">30472905</ArticleId></ArticleIdList></Reference><Reference><Citation>Johannesson E, Ringstr&#xf6;m G, Abrahamsson H, Sadik R. Intervention to increase physical activity in irritable bowel syndrome shows long-term positive effects. World J Gastroenterol. 2015 Jan 14;21(2):600&#x2013;8. doi: 10.3748/wjg.v21.i2.600.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v21.i2.600</ArticleId><ArticleId IdType="pmc">PMC4294172</ArticleId><ArticleId IdType="pubmed">25593485</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Salhy M, Hatlebakk JG, Hausken T. Diet in Irritable Bowel Syndrome (IBS): Interaction with Gut Microbiota and Gut Hormones. Nutrients. 2019;11(8):1824. doi: 10.3390/nu11081824.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu11081824</ArticleId><ArticleId IdType="pmc">PMC6723613</ArticleId><ArticleId IdType="pubmed">31394793</ArticleId></ArticleIdList></Reference><Reference><Citation>McIntosh K, Reed DE, Schneider T, Dang F, et al. FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial. Gut. 2017 Jul;66(7):1241&#x2013;1251. doi: 10.1136/gutjnl-2015-311339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2015-311339</ArticleId><ArticleId IdType="pubmed">26976734</ArticleId></ArticleIdList></Reference><Reference><Citation>Eswaran SL, Chey WD, Han-Markey T, Ball S, Jackson K. A Randomized Controlled Trial Comparing the Low FODMAP Diet vs. Modified NICE Guidelines in US Adults with IBS-D. Am J Gastroenterol. 2016;111(12):1824&#x2013;1832. doi: 10.1038/ajg.2016.434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2016.434</ArticleId><ArticleId IdType="pubmed">27725652</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson PR, Halmos EP, Muir JG. Review article: FODMAPS, prebiotics and gut health-the FODMAP hypothesis revisited. Aliment Pharmacol Ther. 2020;52:233&#x2013;246. doi: 10.1111/apt.15818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15818</ArticleId><ArticleId IdType="pubmed">32562590</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xf6;hn L, St&#xf6;rsrud S, Liljebo T, Collin L, et al. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology. 2015;149(6):1399&#x2013;1407.e2. doi: 10.1053/j.gastro.2015.07.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2015.07.054</ArticleId><ArticleId IdType="pubmed">26255043</ArticleId></ArticleIdList></Reference><Reference><Citation>Staudacher HM, Lomer MC, Anderson JL, Barrett JS, et al. Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr. 2012;142(8):1510&#x2013;1518. doi: 10.3945/jn.112.159285.</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/jn.112.159285</ArticleId><ArticleId IdType="pubmed">22739368</ArticleId></ArticleIdList></Reference><Reference><Citation>Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146(1):67&#x2013;75.e5. doi: 10.1053/j.gastro.2013.09.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2013.09.046</ArticleId><ArticleId IdType="pubmed">24076059</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumitrascu DL, Baban A, Bancila I, Barboi O, et al. Romanian Guidelines for Nonpharmacological Therapy of IBS. J Gastrointestin Liver Dis. 2021;30(2):291&#x2013;306. doi: 10.15403/jgld-3581.</Citation><ArticleIdList><ArticleId IdType="doi">10.15403/jgld-3581</ArticleId><ArticleId IdType="pubmed">33951120</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira AI, Garrido M, Castro-Po&#xe7;as F. Irritable Bowel Syndrome: News from an Old Disorder. GE Port J Gastroenterol. 2020;27(4):255&#x2013;268. doi: 10.1159/000503757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000503757</ArticleId><ArticleId IdType="pmc">PMC7383263</ArticleId><ArticleId IdType="pubmed">32775547</ArticleId></ArticleIdList></Reference><Reference><Citation>Gravina AG, Dallio M, Romeo M, Di Somm A, et al. Adherence and Effects Derived from FODMAP Diet on Irritable Bowel Syndrome: A Real Life Evaluation of a Large Follow-Up Observation. Nutrients. 2020;12(4):928. doi: 10.3390/nu12040928.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12040928</ArticleId><ArticleId IdType="pmc">PMC7231245</ArticleId><ArticleId IdType="pubmed">32230832</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Keeffe M, Jansen C, Martin L, Williams M, et al. Long-term impact of the low-FODMAP diet on gastrointestinal symptoms, dietary intake, patient acceptability, and healthcare utilization in irritable bowel syndrome. Neurogastroenterol Motil. 2018;30(1) doi: 10.1111/nmo.13154. doi: 10.1111/nmo.13154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.13154</ArticleId><ArticleId IdType="doi">10.1111/nmo.13154</ArticleId><ArticleId IdType="pubmed">28707437</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarpato E, Auricchio R, Penagini F, Campanozzi A, et al. Efficacy of the gluten free diet in the management of functional gastrointestinal disorders: a systematic review on behalf of the Italian Society of Paediatrics. Ital J Pediatr. 2019;45(1):9. doi: 10.1186/s13052-019-0606-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13052-019-0606-1</ArticleId><ArticleId IdType="pmc">PMC6329096</ArticleId><ArticleId IdType="pubmed">30635010</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Deng Y, Chu H, Cong Y, et al. Prevalence and presentation of lactose intolerance and effects on dairy product intake in healthy subjects and patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2013;11:262&#x2013;268.e1. doi: 10.1016/j.cgh.2012.11.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2012.11.034</ArticleId><ArticleId IdType="pubmed">23246646</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta D, Ghoshal UC, Misra A, Misra A, et al. Lactose intolerance in patients with irritable bowel syndrome from northern India: a case-control study. J Gastroenterol Hepatol. 2007;22:2261&#x2013;2265. doi: 10.1111/j.1440-1746.2007.04986.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1746.2007.04986.x</ArticleId><ArticleId IdType="pubmed">17559357</ArticleId></ArticleIdList></Reference><Reference><Citation>Varju P, Gede N, Szakacs Z, Hegyi P, et al. Lactose intolerance but not lactose maldigestion is more frequent in patients with irritable bowel syndrome than in healthy controls: A meta-analysis. Neurogastroenterol Motil. 2019;31:e13527. doi: 10.1111/nmo.13527.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.13527</ArticleId><ArticleId IdType="pmc">PMC7379306</ArticleId><ArticleId IdType="pubmed">30560578</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford AC, Lacy BE, Talley NJ. Irritable Bowel Syndrome. N Engl J Med. 2017;376:2566&#x2013;2578. doi: 10.1056/NEJMra1607547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1607547</ArticleId><ArticleId IdType="pubmed">28657875</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagarajan N, Morden A, Bischof D, King EA, et al. The role of fiber supplementation in the treatment of irritable bowel syndrome: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2015;27:1002&#x2013;1010. doi: 10.1097/MEG.0000000000000425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MEG.0000000000000425</ArticleId><ArticleId IdType="pubmed">26148247</ArticleId></ArticleIdList></Reference><Reference><Citation>Moayyedi P, Quigley EM, Lacy BE, Lembo AJ, et al. The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109(9):1367&#x2013;1374. doi: 10.1038/ajg.2014.195.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2014.195</ArticleId><ArticleId IdType="pubmed">25070054</ArticleId></ArticleIdList></Reference><Reference><Citation>McRorie JW. Evidence-Based Approach to Fiber Supplementsand Clinically Meaningful Health Benefits, Part 1: What to Look for and How to Recommend an Effective Fiber Therapy. Nutr Today. 2015;50:82&#x2013;89. doi: 10.1097/NT.0000000000000082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NT.0000000000000082</ArticleId><ArticleId IdType="pmc">PMC4415962</ArticleId><ArticleId IdType="pubmed">25972618</ArticleId></ArticleIdList></Reference><Reference><Citation>Moayyedi P, Andrews CN, MacQueen G, Korownyk C, et al. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS). J Can Assoc Gastroenterol. 2019 Apr;2(1):6&#x2013;29. doi: 10.1093/jcag/gwy071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jcag/gwy071</ArticleId><ArticleId IdType="pmc">PMC6507291</ArticleId><ArticleId IdType="pubmed">31294724</ArticleId></ArticleIdList></Reference><Reference><Citation>Bijkerk CJ, de Wit NJ, Muris JW, Whorwell PJ, et al. Soluble or insoluble fibre in irritable bowel syndrome in primary care?Randomised placebo controlled trial. BMJ. 2009;339:b3154. doi: 10.1136/bmj.b3154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.b3154</ArticleId><ArticleId IdType="pmc">PMC3272664</ArticleId><ArticleId IdType="pubmed">19713235</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh B. Psyllium as therapeutic and drug delivery agent. Int J Pharm. 2007;334(1-2):1&#x2013;14. doi: 10.1016/j.ijpharm.2007.01.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2007.01.028</ArticleId><ArticleId IdType="pubmed">17329047</ArticleId></ArticleIdList></Reference><Reference><Citation>Muir J. An Overview of Fiber and Fiber Supplements for Irritable Bowel Syndrome. Gastroenterol Hepatol (N Y) 2019;15:387&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6676347</ArticleId><ArticleId IdType="pubmed">31391809</ArticleId></ArticleIdList></Reference><Reference><Citation>Toskes PP, Connery KL, Ritchey TW. Calcium polycarbophil compared with placebo in irritable bowel syndrome. Aliment Pharmacol Ther. 1993;7(1):87&#x2013;92. doi: 10.1111/j.1365-2036.1993.tb00074.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.1993.tb00074.x</ArticleId><ArticleId IdType="pubmed">8439642</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenzie YA, Bowyer RK, Leach H, Gulia P, et al. British Dietetic Association systematic review and evidence-based practice guidelines for the dietary management of irritable bowel syndrome in adults (2016 update). J Hum Nutr Diet. 2016 Oct;29(5):549&#x2013;75. doi: 10.1111/jhn.12385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jhn.12385</ArticleId><ArticleId IdType="pubmed">27272325</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson GR, Hutkins R, Sanders ME, Prescott SL, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017 Aug;14(8):491&#x2013;502. doi: 10.1038/nrgastro.2017.75.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2017.75</ArticleId><ArticleId IdType="pubmed">28611480</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill C, Guarner F, Reid G, Gibson GR, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014 Aug;11(8):506&#x2013;14. doi: 10.1038/nrgastro.2014.66.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2014.66</ArticleId><ArticleId IdType="pubmed">24912386</ArticleId></ArticleIdList></Reference><Reference><Citation>Distrutti E, Monaldi L, Ricci P, Fiorucci S. Gut microbiota role in irritable bowel syndrome: New therapeutic strategies. World J Gastroenterol. 2016;22(7):2219&#x2013;2241. doi: 10.3748/wjg.v22.i7.2219.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v22.i7.2219</ArticleId><ArticleId IdType="pmc">PMC4734998</ArticleId><ArticleId IdType="pubmed">26900286</ArticleId></ArticleIdList></Reference><Reference><Citation>Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J. 2017 May 16;474(11):1823&#x2013;1836. doi: 10.1042/BCJ20160510.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BCJ20160510</ArticleId><ArticleId IdType="pmc">PMC5433529</ArticleId><ArticleId IdType="pubmed">28512250</ArticleId></ArticleIdList></Reference><Reference><Citation>Mari A, Abu Bake F, Mahamid M, Sbeit W, Khoury T. The Evolving Role of Gut Microbiota in the Management of Irritable Bowel Syndrome: An Overview of the Current Knowledge. J Clin Med. 2020;9(3):685. doi: 10.3390/jcm9030685.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9030685</ArticleId><ArticleId IdType="pmc">PMC7141230</ArticleId><ArticleId IdType="pubmed">32143424</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodi&#xf1;o-Janeiro BK, Vicario M, Alonso-Cotoner C, Pascua-Garc&#xed;a R, Santos J. A Review of Microbiota and Irritable Bowel Syndrome: Future in Therapies. Adv Ther. 2018;35(3):289&#x2013;310. doi: 10.1007/s12325-018-0673-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12325-018-0673-5</ArticleId><ArticleId IdType="pmc">PMC5859043</ArticleId><ArticleId IdType="pubmed">29498019</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenzie YA, Thompson J, Gulia P, Lomer MC, (IBS Dietetic Guideline Review Group on behalf of Gastroenterology Specialist Group of the British Dietetic Association) British Dietetic Association systematic review of systematic reviews and evidence-based practice guidelines for the use of probiotics in the management of irritable bowel syndrome in adults (2016 update). J Hum Nutr Diet. 2016;29(5):576&#x2013;592. doi: 10.1111/jhn.12386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jhn.12386</ArticleId><ArticleId IdType="pubmed">27265510</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford AC, Harris LA, Lacy BE, Quigley EMM, Moayyedi P. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther. 2018 Nov;48(10):1044&#x2013;1060. doi: 10.1111/apt.15001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15001</ArticleId><ArticleId IdType="pubmed">30294792</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukudo S, Okumura T, Inamori M, Okuyama Y, et al. Evidence-based clinical practice guidelines for irritable bowel syndrome 2020. J Gastroenterol. 2021;56(3):193&#x2013;217. doi: 10.1007/s00535-020-01746-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00535-020-01746-z</ArticleId><ArticleId IdType="pmc">PMC7932982</ArticleId><ArticleId IdType="pubmed">33538894</ArticleId></ArticleIdList></Reference><Reference><Citation>Herndon CC, Wang YP, Lu CL. Targeting the gut microbiota for the treatment of irritable bowel syndrome. Kaohsiung J Med Sci. 2020;36(3):160&#x2013;170. doi: 10.1002/kjm2.12154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/kjm2.12154</ArticleId><ArticleId IdType="pmc">PMC11896346</ArticleId><ArticleId IdType="pubmed">31782606</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan F, Ni H, Asche CV, Kim M, et al. Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis. Curr Med Res Opin. 2017;33(7):1191&#x2013;1197. doi: 10.1080/03007995.2017.1292230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03007995.2017.1292230</ArticleId><ArticleId IdType="pubmed">28166427</ArticleId></ArticleIdList></Reference><Reference><Citation>Cayzeele-Decherf A, Pelerin F, Leuillet S, Douillard B, et al. Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: An individual subject meta-analysis. World J Gastroenterol. 2017;23(2):336&#x2013;344. doi: 10.3748/wjg.v23.i2.336.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v23.i2.336</ArticleId><ArticleId IdType="pmc">PMC5236513</ArticleId><ArticleId IdType="pubmed">28127207</ArticleId></ArticleIdList></Reference><Reference><Citation>Fikree A, Byrne P. Management of functional gastrointestinal disorders. Clin Med (Lond). 2021;21(1):44&#x2013;52. doi: 10.7861/clinmed.2020-0980.</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmed.2020-0980</ArticleId><ArticleId IdType="pmc">PMC7850201</ArticleId><ArticleId IdType="pubmed">33479067</ArticleId></ArticleIdList></Reference><Reference><Citation>Doron S, Snydman DR. Risk and safety of probiotics. Clin Infect Dis. 2015;60(Suppl 2(Suppl 2)):S129&#x2013;S134. doi: 10.1093/cid/civ085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/civ085</ArticleId><ArticleId IdType="pmc">PMC4490230</ArticleId><ArticleId IdType="pubmed">25922398</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee BJ, Bak YT. Irritable bowel syndrome, gut microbiota and probiotics. J Neurogastroenterol Motil. 2011;17(3):252&#x2013;266. doi: 10.5056/jnm.2011.17.3.252.</Citation><ArticleIdList><ArticleId IdType="doi">10.5056/jnm.2011.17.3.252</ArticleId><ArticleId IdType="pmc">PMC3155061</ArticleId><ArticleId IdType="pubmed">21860817</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22314561</PMID><DateCompleted><Year>2012</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1899-1505</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><Issue>6</Issue><PubDate><Year>2011</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of physiology and pharmacology : an official journal of the Polish Physiological Society</Title><ISOAbbreviation>J Physiol Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options.</ArticleTitle><Pagination><StartPage>591</StartPage><EndPage>599</EndPage><MedlinePgn>591-9</MedlinePgn></Pagination><Abstract><AbstractText>Stress, which is defined as an acute threat to homeostasis, shows both short- and long-term effects on the functions of the gastrointestinal tract. Exposure to stress results in alterations of the brain-gut interactions ("brain-gut axis") ultimately leading to the development of a broad array of gastrointestinal disorders including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and other functional gastrointestinal diseases, food antigen-related adverse responses, peptic ulcer and gastroesophageal reflux disease (GERD). The major effects of stress on gut physiology include: 1) alterations in gastrointestinal motility; 2) increase in visceral perception; 3) changes in gastrointestinal secretion; 4) increase in intestinal permeability; 5) negative effects on regenerative capacity of gastrointestinal mucosa and mucosal blood flow; and 6) negative effects on intestinal microbiota. Mast cells (MC) are important effectors of brain-gut axis that translate the stress signals into the release of a wide range of neurotransmitters and proinflammatory cytokines, which may profoundly affect the gastrointestinal physiology. IBS represents the most important gastrointestinal disorder in humans, and is characterized by chronic or recurrent pain associated with altered bowel motility. The diagnostic testing for IBS patients include routine blood tests, stool tests, celiac disease serology, abdominal sonography, breath testing to rule out carbohydrate (lactose, fructose, etc.) intolerance and small intestinal bacterial overgrowth. Colonoscopy is recommended if alarming symptoms are present or to obtain colonic biopsies especially in patients with diarrhoea predominant IBS. The management of IBS is based on a multifactorial approach and includes pharmacotherapy targeted against the predominant symptom, behavioural and psychological treatment, dietary alterations, education, reassurance and effective patient-physician relationship. When evaluating for the stress-induced condition in the upper GI tract, the diagnostic testing includes mainly blood tests and gastroscopy to rule out GERD and peptic ulcer disease. The therapy for these conditions is mainly based on the inhibition of gastric acid by proton pump inhibitors and eradication of Helicobacter pylori-infection. Additionally, melatonin an important mediator of brain gut axis has been shown to exhibit important protective effects against stress-induced lesions in the gastrointestinal tract. Finally, probiotics may profoundly affect the brain-gut interactions ("microbiome-gut-brain axis") and attenuate the development of stress-induced disorders in both the upper and lower gastrointestinal tract. Further studies on the brain-gut axis are needed to open new therapeutic avenues in the future.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Konturek</LastName><ForeName>Peter C</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Department of Medicine, Thuringia Clinic Saalfeld, Teaching Hospital of the University Jena, Germany. pkonturek@thueringen-kliniken.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brzozowski</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Konturek</LastName><ForeName>S J</ForeName><Initials>SJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>J Physiol Pharmacol</MedlineTA><NlmUniqueID>9114501</NlmUniqueID><ISSNLinking>0867-5910</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000930">Antidiarrheals</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000930" MajorTopicYN="N">Antidiarrheals</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017615" MajorTopicYN="N">Enteric Nervous System</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005767" MajorTopicYN="N">Gastrointestinal Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D041981" MajorTopicYN="N">Gastrointestinal Tract</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="N">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013315" MajorTopicYN="N">Stress, Psychological</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22314561</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>